{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:37Z","timestamp":1787026657445,"version":"build-2736575974"},"reference-count":200,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Psoriatic arthritis (PsA) is a chronic inflammatory disease that presents with psoriasis (PsO), peripheral and axial arthropathy. The heterogeneity of disease presentation leads to the term \u201cpsoriatic disease (PsD)\u201d which is thought to better encompass the range of clinical manifestations. PsA is associated with several comorbidities such as cardiovascular diseases, metabolic syndrome and other extra-articular manifestations including uveitis, and inflammatory bowel disease (IBD). While novel therapeutics are being developed following advances in our understanding of the pathogenesis of the disease, the diverse combinations of PsA with its various comorbidities still pose a clinical challenge in managing patients with PsA. This article reviews our current understanding of the pathogenesis of PsA and how various pathways in the pathogenesis lead to the two comorbid extra-articular manifestations \u2013 uveitis and IBD. We also review current evidence of treatment strategies in managing patients with PsA with comorbidities of uveitis and\/or IBD.<\/jats:p>","DOI":"10.3389\/fmed.2021.737256","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:46:00Z","timestamp":1631753160000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Managing Psoriatic Arthritis With Inflammatory Bowel Disease and\/or Uveitis"],"prefix":"10.3389","volume":"8","author":[{"given":"Alfred Yu Ting","family":"Chia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys Wei Xin","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita Sook Yee","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Webber","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Kit Yeong","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Ying","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"New England Journal of Medicine."},{"key":"B2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101689","article-title":"Cardiovascular disease and depression in psoriatic arthritis: multidimensional comorbidities requiring multidisciplinary management","volume":"101689","author":"So","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"528","DOI":"10.5694\/mja2.50591","article-title":"Beyond skin deep: addressing comorbidities in psoriasis","volume":"212","author":"Kovitwanichkanont","year":"2020","journal-title":"Med J Aust."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1759720x20962623","DOI":"10.1177\/1759720X20962623","article-title":"Choosing the right treatment for patients with psoriatic arthritis","volume":"12","author":"Noviani","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1053\/j.sempedsurg.2017.10.003","article-title":"Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, disease phenotypes","volume":"26","author":"Yu","year":"2017","journal-title":"Semin Pediatr Surg."},{"key":"B8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/1756283X10361304","article-title":"Current trends in inflammatory bowel disease: the natural history","volume":"3","author":"Langholz","year":"2010","journal-title":"Therap Adv Gastroenterol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12178-011-9085-8","article-title":"Inflammatory bowel disease associated arthropathy","volume":"4","author":"Arvikar","year":"2011","journal-title":"Curr Rev Musculoskelet Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3109\/07853890903559724","article-title":"Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management","volume":"42","author":"Larsen","year":"2010","journal-title":"Ann Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.3748\/wjg.15.5517","article-title":"Rheumatic manifestations of inflammatory bowel disease","volume":"15","author":"Rodr\u00edguez-Reyna","year":"2009","journal-title":"World J Gastroenterol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.autrev.2013.06.006","article-title":"Rheumatic manifestations in inflammatory bowel disease","volume":"13","author":"Atzeni","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.3748\/wjg.15.2443","article-title":"Gastrointestinal lesions associated with spondyloarthropathies","volume":"15","author":"Orlando","year":"2009","journal-title":"World J Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","article-title":"Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women","volume":"72","author":"Li","year":"2013","journal-title":"Ann Rheumatic Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1007\/s10067-016-3374-y","article-title":"Gastrointestinal comorbidities in patients with psoriatic arthritis","volume":"35","author":"Zohar","year":"2016","journal-title":"Clin Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2009.02.015","article-title":"The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis","volume":"61","author":"Makredes","year":"2009","journal-title":"J Am Acad Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1097\/MIB.0000000000001169","article-title":"Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease","volume":"23","author":"Eppinga","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3899\/jrheum.161216","article-title":"Detection of crohn disease in patients with spondyloarthropathy: the SpACE capsule study","volume":"45","author":"Kopylov","year":"2018","journal-title":"J Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/rheumatology\/XXVII.suppl_2.95","article-title":"Ileocolonoscopic findings in seronegative spondylarthropathies","volume":"2","author":"Mielants","year":"1988","journal-title":"Br J Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3109\/03009749709065722","article-title":"Ileocolonoscopic and histologic studies of Korean patients with ankylosing spondylitis","volume":"26","author":"Lee","year":"1997","journal-title":"Scand J Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/art.1780370105","article-title":"High frequency of silent inflammatory bowel disease in spondylarthropathy","volume":"37","author":"Leirisalo-Repo","year":"1994","journal-title":"Arthritis Rheum."},{"key":"B23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","article-title":"Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model","volume":"72","author":"Van","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/annrheumdis-2013-203854","article-title":"Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort","volume":"73","author":"Van","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1053\/gast.1996.v110.pm8964393","article-title":"Long-term evolution of gut inflammation in patients with spondyloarthropathy","volume":"110","author":"De","year":"1996","journal-title":"Gastroenterology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1136\/annrheumdis-2014-205253","article-title":"The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1136\/annrheumdis-2020-eular.4806","article-title":"AB0829 inflammatoy bowel disease in psoriatic arthritis. Study of 306 patients from a single university center, prevalence clinical features and relationship to biologic therapy","volume":"79","author":"Sanchez-Bilbao","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/annrheumdis-2016-209853","article-title":"Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis","volume":"76","author":"Jadon","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00281-014-0433-9","article-title":"Autoimmune and autoinflammatory mechanisms in uveitis","volume":"36","author":"Lee","year":"2014","journal-title":"Semin Immunopathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"650","DOI":"10.18240\/ijo.2020.04.19","article-title":"Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studies","volume":"13","author":"Li","year":"2020","journal-title":"Int J Ophthalmol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/jcm10051031","article-title":"Ocular manifestations in psoriasis screening (OcMaPS) questionnaire: a useful tool to reveal misdiagnosed ocular involvement in psoriasis","volume":"10","author":"Ruggiero","year":"2021","journal-title":"J Clin Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3109\/08820538.2016.1170161","article-title":"Psoriasis and psoriatic arthritis-related uveitis: different ophthalmological manifestations and ocular inflammation features","volume":"32","author":"Abbouda","year":"2017","journal-title":"Semin Ophthalmol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"629401","DOI":"10.3389\/fnins.2021.629401","article-title":"Retinal vascular assessment in psoriasis: a multicenter study","volume":"15","author":"Castellino","year":"2021","journal-title":"Front Neurosci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/ard.2007.075754","article-title":"Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review","volume":"67","author":"Zeboulon","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1756-185X.2012.01736.x","article-title":"Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study","volume":"15","author":"Niccoli","year":"2012","journal-title":"Int J Rheum Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jamadermatol.2015.1986","article-title":"Association of psoriatic disease with uveitis: a danish nationwide cohort study","volume":"151","author":"Egeberg","year":"2015","journal-title":"JAMA Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1001\/jamaophthalmol.2017.0569","article-title":"Risk of uveitis among people with psoriasis: a nationwide cohort study","volume":"135","author":"Chi","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11926-015-0536-x","article-title":"Acute anterior uveitis and spondyloarthritis: more than meets the eye","volume":"17","author":"Khan","year":"2015","journal-title":"Curr Rheumatol Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/ard.59.1.67","article-title":"Characterisation of uveitis in patients with psoriatic arthritis","volume":"59","author":"Paiva","year":"2000","journal-title":"Ann Rheum Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10067-014-2652-9","article-title":"Extra-articular manifestations in psoriatic arthritis patients","volume":"34","author":"Peluso","year":"2015","journal-title":"Clin Rheumatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/sarh.2002.28798","article-title":"Clinical features and predictive factors in psoriatic arthritis-related uveitis","volume":"31","author":"Queiro","year":"2002","journal-title":"Semin Arthritis Rheum."},{"key":"B44","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/bjd.12731","article-title":"Psoriasis and uveitis\u2013should we be asking about eye symptoms?","volume":"170","author":"Burden-Teh","year":"2014","journal-title":"Br J Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"101691","DOI":"10.1016\/j.berh.2021.101691","article-title":"Clinical and molecular significance of genetic loci associated with psoriatic arthritis","volume":"35","author":"O'Rielly","year":"2021","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/annrheumdis-2014-205461","article-title":"Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype","volume":"75","author":"Haroon","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/art.33415","article-title":"associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype","volume":"64","author":"Winchester","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B48","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1172\/JCI109903","article-title":"Histocompatibility alloantigens in psoriasis and psoriatic arthritis. Evidence for the influence of multiple genes in the major histocompatibility complex","volume":"66","author":"Murray","year":"1980","journal-title":"J Clin Invest."},{"key":"B49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0950-3579(94)80018-9","article-title":"Psoriatic arthritis. Genetics and HLA antigens Baillieres","volume":"8","author":"Eastmond","year":"1994","journal-title":"Clin Rheumatol."},{"key":"B50","first-page":"730","article-title":"HLA markers and progression in psoriatic arthritis","volume":"25","author":"Gladman","year":"1998","journal-title":"J Rheumatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/art.1780210112","article-title":"Association between HLA-BW38 and peripheral psoriatic arthritis","volume":"21","author":"Espinoza","year":"1978","journal-title":"Arthritis Rheum."},{"key":"B52","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1038\/ncomms8741","article-title":"Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis","volume":"6","author":"Bowes","year":"2015","journal-title":"Nat Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ng.688","article-title":"Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis","volume":"42","author":"H\u00fcffmeier","year":"2010","journal-title":"Nat Genet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture","volume":"97","author":"Stuart","year":"2015","journal-title":"Am J Hum Genet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/ar4071","article-title":"New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis","volume":"14","author":"Doyle","year":"2012","journal-title":"Arthritis Res Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"596086","DOI":"10.3389\/fimmu.2020.596086","article-title":"The IL-17\/IL-23 axis and its genetic contribution to psoriatic arthritis","volume":"11","author":"Vecellio","year":"2020","journal-title":"Front Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","article-title":"Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells","volume":"73","author":"Jacques","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.4049\/jimmunol.1300274","article-title":"Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase\/prostaglandin E2 pathway, independent of IL-23","volume":"191","author":"Paulissen","year":"2013","journal-title":"J Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0030297","article-title":"proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/ar1864","article-title":"Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis","volume":"8","author":"Jongbloed","year":"2006","journal-title":"Arthritis Res Ther."},{"key":"B63","first-page":"374","article-title":"Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity?","volume":"34","author":"Candia","year":"2007","journal-title":"J Rheumatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/ard.2004.020719","article-title":"TNFalpha therapy in psoriatic arthritis and psoriasis","volume":"63","author":"Mease","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1002\/art.39261","article-title":"Brief report: enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid","volume":"67","author":"Leijten","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.4049\/jimmunol.1700596","article-title":"Cutting edge: homeostasis of innate lymphoid cells is imbalanced in psoriatic arthritis","volume":"200","author":"Soare","year":"2018","journal-title":"J Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1038\/jid.2014.261","article-title":"The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells","volume":"134","author":"Teunissen","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"154855","DOI":"10.1016\/j.cyto.2019.154855","article-title":"Functional significance of MAIT cells in psoriatic arthritis","volume":"125","author":"Raychaudhuri","year":"2020","journal-title":"Cytokine."},{"key":"B69","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/cei.12853","article-title":"Interleukin (IL)-9\/IL-9R axis drives \u03b3\u03b4 T cells activation in psoriatic arthritis patients","volume":"186","author":"Guggino","year":"2016","journal-title":"Clin Exp Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41423-021-00644-5","article-title":"Local and systemic effects of IL-17 in joint inflammation: a historical perspective from discovery to targeting","volume":"18","author":"Miossec","year":"2021","journal-title":"Cell Mol Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1182\/blood-2008-05-155408","article-title":"Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion","volume":"112","author":"Chizzolini","year":"2008","journal-title":"Blood."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/art.41156","article-title":"Polyfunctional Proinflammatory, Tissue-Resident Memory Phenotype and Function of Synovial Interleukin-17A+CD8+ T Cells in Psoriatic Arthritis","volume":"72","author":"Steel","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10067-015-2961-7","article-title":"Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis","volume":"34","author":"Raychaudhuri","year":"2015","journal-title":"Clin Rheumatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.3748\/wjg.15.2449","article-title":"Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease","volume":"15","author":"Salvarani","year":"2009","journal-title":"World J Gastroenterol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"387891","DOI":"10.1155\/2015\/387891","article-title":"Management of musculoskeletal manifestations in inflammatory bowel disease","volume":"2015","author":"Sheth","year":"2015","journal-title":"Gastroenterol Res Pract."},{"key":"B78","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/ng.3176","article-title":"High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis","volume":"47","author":"Goyette","year":"2015","journal-title":"Nat Genet."},{"key":"B79","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0016-5085(00)70209-5","article-title":"Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease","volume":"118","author":"Orchard","year":"2000","journal-title":"Gastroenterology."},{"key":"B80","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/annrheumdis-2018-213779","article-title":"HLA class I and II alleles in susceptibility to ankylosing spondylitis","volume":"78","author":"Reveille","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nri1132","article-title":"The immunological and genetic basis of inflammatory bowel disease","volume":"3","author":"Bouma","year":"2003","journal-title":"Nat Rev Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.crohns.2009.11.005","article-title":"The joint-gut axis in inflammatory bowel diseases","volume":"4","author":"Brakenhoff","year":"2010","journal-title":"J Crohns Colitis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/ard.2004.021774","article-title":"Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease","volume":"63","author":"Peeters","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/35079114","article-title":"A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease","volume":"411","author":"Ogura","year":"2001","journal-title":"Nature."},{"key":"B85","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Targeted Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e1001195","DOI":"10.1371\/journal.pgen.1001195","article-title":"Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease","volume":"6","author":"Danoy","year":"2010","journal-title":"PLoS Genet."},{"key":"B88","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/gut.2003.025403","article-title":"Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease","volume":"53","author":"Ott","year":"2004","journal-title":"Gut."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1097\/01.mib.0000235828.09305.0c","article-title":"Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis","volume":"12","author":"Martinez-Medina","year":"2006","journal-title":"Inflamm Bowel Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"15064","DOI":"10.1073\/pnas.0803124105","article-title":"The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria","volume":"105","author":"Johansson","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B91","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41584-020-0454-9","article-title":"Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis","volume":"16","author":"Gracey","year":"2020","journal-title":"Nat Rev Rheumatol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/BOR.0b013e3283393807","article-title":"Interactions between gut inflammation and arthritis\/spondylitis","volume":"22","author":"Jacques","year":"2010","journal-title":"Curr Opin Rheumatol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"Cd012774","DOI":"10.1002\/14651858.CD012774.pub2","article-title":"Fecal transplantation for treatment of inflammatory bowel disease","volume":"11","author":"Imdad","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"B94","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/1751-2980.12933","article-title":"Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: A systematic review and meta-analysis","volume":"21","author":"Zhao","year":"2020","journal-title":"J Dig Dis."},{"key":"B95","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial","volume":"149","author":"Moayyedi","year":"2015","journal-title":"Gastroenterology"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220910","article-title":"Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial","author":"Kragsnaes","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B97","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/cei.12277","article-title":"Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases","volume":"176","author":"Serriari","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/eji.1830210429","article-title":"major fraction of human intraepithelial lymphocytes simultaneously expresses the gamma\/delta T cell receptor, the CD8 accessory molecule and preferentially uses the V delta 1 gene segment","volume":"21","author":"Deusch","year":"1991","journal-title":"Eur J Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/ecco-jcc\/jjx039","article-title":"Gammadelta T cells in crohn's disease: a new player in the disease pathogenesis?","volume":"11","author":"Catalan-Serra","year":"2017","journal-title":"Journal of Crohn's and Colitis."},{"key":"B100","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000068147","article-title":"Role of gamma delta T cells in inflammatory bowel disease","volume":"70","author":"K\u00fchl","year":"2002","journal-title":"Pathobiology."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1084\/jem.20080397","article-title":"Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor","volume":"205","author":"Cosmi","year":"2008","journal-title":"J Exp Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1023\/B:JOCI.0000018066.46279.6b","article-title":"Increased expression of CCL20 in human inflammatory bowel disease","volume":"24","author":"Kaser","year":"2004","journal-title":"J Clin Immunol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1002\/eji.200324347","article-title":"CCR6 has a non-redundant role in the development of inflammatory bowel disease","volume":"33","author":"Varona","year":"2003","journal-title":"Eur J Immunol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut."},{"key":"B105","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/ibd.20339","article-title":"Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F pHis161Arg polymorphism in IBD","volume":"14","author":"Seiderer","year":"2008","journal-title":"Inflamm Bowel Dis."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1136\/gut.2007.135053","article-title":"IL23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn's disease","volume":"57","author":"Kobayashi","year":"2008","journal-title":"Gut."},{"key":"B107","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"Raine IL-12 T, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clim.2003.09.013","article-title":"Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice","volume":"110","author":"Ogawa","year":"2004","journal-title":"Clin Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.14309\/crj.2018.56","article-title":"Rapid onset of inflammatory bowel disease after receiving secukinumab infusion","volume":"5","author":"Wang","year":"2018","journal-title":"ACG Case Rep J."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B111","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3109\/09273948.2011.559302","article-title":"An update on the genetics of HLA B27-associated acute anterior uveitis","volume":"19","author":"Martin","year":"2011","journal-title":"Ocul Immunol Inflamm."},{"key":"B112","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0039-6257(91)90005-Z","article-title":"Acute anterior uveitis and HLA-B27","volume":"36","author":"Wakefield","year":"1991","journal-title":"Surv Ophthalmol."},{"key":"B113","first-page":"295","article-title":"Association of HLA-A2 with uveitis in HLA-B27 positive patients with ankylosing spondylitis","volume":"8","author":"Khan","year":"1981","journal-title":"J Rheumatol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/art.1780380414","article-title":"HLA-DR8 and acute anterior uveitis in ankylosing spondylitis","volume":"38","author":"Monowarul","year":"1995","journal-title":"Arthritis Rheum."},{"key":"B115","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1053\/gast.2002.35396","article-title":"Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes","volume":"123","author":"Orchard","year":"2002","journal-title":"Gastroenterology."},{"key":"B116","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.patbio.2014.10.007","article-title":"Association study of MICA-TM and HLA-class I polymorphism with uveitis in South Tunisian population","volume":"63","author":"Loukil","year":"2015","journal-title":"Pathol Biol (Paris)."},{"key":"B117","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0002-9394(98)00100-7","article-title":"Association between MICA gene A4 allele and acute anterior uveitis in white patients with and without HLA-B27","volume":"126","author":"Goto","year":"1998","journal-title":"Am J Ophthalmol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1111\/aos.12104","article-title":"Role of IL-10 gene polymorphisms in intermediate and HLA-B27-associated uveitis","volume":"91","author":"Lindner","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1186\/ar4293","article-title":"receptor-associated factor 5 gene confers genetic predisposition to acute anterior uveitis and pediatric uveitis","volume":"15","author":"Xiang","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B120","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3109\/09273948.2010.538798","article-title":"Killer immunoglobulin-like receptor genes in uveitis","volume":"19","author":"Levinson","year":"2011","journal-title":"Ocul Immunol Inflamm."},{"key":"B121","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/art.38873","article-title":"Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis","volume":"67","author":"Robinson","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3410\/B2-3","article-title":"Ocular immune privilege","volume":"2","author":"Zhou","year":"2010","journal-title":"F1000 Biol Rep."},{"key":"B123","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ajo.2018.02.019","article-title":"Dick AAutoimmunity D, Autoinflammation, and Infection in Uveitis","volume":"189","author":"Forrester","year":"2018","journal-title":"Am J Ophthalmol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"11745","DOI":"10.1038\/s41598-017-12163-3","article-title":"Short chain fatty acids ameliorate immune-mediated uveitis partially by altering migration of lymphocytes from the intestine","volume":"7","author":"Nakamura","year":"2017","journal-title":"Sci Rep."},{"key":"B125","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4049\/jimmunol.198.Supp.218.10","article-title":"Gut microbiota as a source of signals that trigger spontaneous ocular autoimmunity","volume":"198","author":"Salvador","year":"2017","journal-title":"J Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2015.147","article-title":"'MHC-I-opathy'\u2014unified concept for spondyloarthritis and Beh\u00e7et disease","volume":"11","author":"McGonagle","year":"2015","journal-title":"Nat Rev Rheumatol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/art.39732","article-title":"Interleukin-23-Dependent \u03b3\/\u03b4 T Cells Produce Interleukin-17 and Accumulate in the Enthesis. Aortic Valve, and Ciliary Body in Mice Arthritis","volume":"68","author":"Reinhardt","year":"2016","journal-title":"Rheumatol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3109\/09273948.2013.815786","article-title":"Elevated serum levels of interleukin-17A in uveitis patients","volume":"21","author":"Jawad","year":"2013","journal-title":"Ocul Immunol Inflamm."},{"key":"B129","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nm1585","article-title":"TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Amadi-Obi","year":"2007","journal-title":"Nat Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.4049\/jimmunol.180.9.6070","article-title":"Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases","volume":"180","author":"Liu","year":"2008","journal-title":"J Immunol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.exer.2010.04.009","article-title":"Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses","volume":"91","author":"Hohki","year":"2010","journal-title":"Exp Eye Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12026-008-8031-3","article-title":"Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells","volume":"42","author":"Caspi","year":"2008","journal-title":"Immunol Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/PTT.S179182","article-title":"Psoriasis and uveitis: links and risks","volume":"9","author":"Fotiadou","year":"2019","journal-title":"Psoriasis (Auckl)."},{"key":"B134","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-218456","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (2015). Treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1097\/MIB.0000000000000816","article-title":"Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-analysis","volume":"22","author":"Reinink","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"874","DOI":"10.14309\/ajg.0000000000000183","article-title":"Treat-to-target update in ulcerative colitis: a systematic review","volume":"114","author":"Ungaro","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/ecco-jcc\/jjz131","article-title":"Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review","volume":"14","author":"Colombel","year":"2020","journal-title":"J Crohns Colitis."},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.10.008","article-title":"Rates of intestinal resection and colectomy in inflammatory bowel disease patients after initiation of biologics: a cohort study","author":"Khoudari","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"ECCO, 3rd European evidence-based consensus on the diagnosis and management of crohn's disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2016","journal-title":"J Crohn's Colitis."},{"key":"B144","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"Clinical guideline: management of crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis."},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003574.pub2","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease","volume":"4","author":"Akobeng","year":"2003","journal-title":"Cochrane Database System Rev."},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006893","article-title":"Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease","volume":"1","author":"Behm","year":"2008","journal-title":"Cochrane Database System Rev."},{"key":"B148","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut."},{"key":"B150","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med."},{"key":"B151","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet."},{"key":"B155","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/ajg.2010.78","article-title":"Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data","volume":"105","author":"Schreiber","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.cgh.2010.04.021","article-title":"Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A Randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med."},{"key":"B162","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"New Engl J Med."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut."},{"key":"B166","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet."},{"key":"B167","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B168","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1046\/j.1572-0241.2003.04010.x","article-title":"Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries","volume":"99","author":"Lichtenstein","year":"2004","journal-title":"Am J Gastroenterol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1053\/j.gastro.2008.07.069","article-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology."},{"key":"B170","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/MEG.0000000000000296","article-title":"Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn's disease: predictors of efficacy in clinical practice","volume":"27","author":"Echarri","year":"2015","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3389\/fmed.2019.00234","article-title":"Administration timing is the best clinical outcome predictor for adalimumab administration in Crohn's disease","volume":"6","author":"Mastronardi","year":"2019","journal-title":"Frontiers in medicine."},{"key":"B172","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med."},{"key":"B173","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"B174","unstructured":"Risankizumab (SKYRIZI\u00ae) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease2021"},{"key":"B175","unstructured":"Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI\u00ae) Achieved Endoscopic Response and Clinical Remission at One Year2021"},{"key":"B176","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut."},{"key":"B177","article-title":"Incidence of inflammatory bowel disease among patients treated with ixekizumab: an update on adjudicated data from an integrated database of patients with psoriasis and psoriatic arthritis","author":"Genovese","year":"2018","journal-title":"ACR\/ARHP Annual Meeting. 2018: Arthritis Rheumatol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut."},{"key":"B179","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"B180","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med."},{"key":"B181","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"B182","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology."},{"key":"B183","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"B184","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"New Engl J Med."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"New Engl J Med."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"New Engl J Med."},{"key":"B187","unstructured":"A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)2021"},{"key":"B188","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4103\/0301-4738.114099","article-title":"Medical management of uveitis- current trends","volume":"61","author":"Babu","year":"2013","journal-title":"Indian J Ophthalmol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.survophthal.2015.06.004","article-title":"Anti-tumor necrosis factor-\u03b1 therapy in uveitis","volume":"60","author":"Cordero-Coma","year":"2015","journal-title":"Surv Ophthalmol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet."},{"key":"B192","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3899\/jrheum.180312","article-title":"Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab- The GO-EASY study","volume":"46","author":"van","year":"2019","journal-title":"J Rheumatol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/annrheumdis-2020-eular.3747","article-title":"THU0379 reduction of anterior uveitis flares in patients with axial spondyloarthritis following one year of treatment with certolizumab pegol: 48-week interim results from a 96-week open-label study","volume":"79","author":"Van","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B194","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology."},{"key":"B195","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","volume":"122","author":"Letko","year":"2015","journal-title":"Ophthalmology."},{"key":"B196","unstructured":"Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study) SenHN"},{"key":"B197","unstructured":"Safety of Ustekinumab, a Human Monoclonal Anti-IL-12\/IL-23 Antibody, in Patients With Beh\u00e7et Disease (STELABEC) Terrier EfficacyB"},{"key":"B198","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B199","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s12325-019-00901-0","article-title":"Multidisciplinary management of psoriatic arthritis: the benefits of a comprehensive approach","volume":"36","author":"Visalli","year":"2019","journal-title":"Adv Ther."},{"key":"B200","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.adengl.2014.01.002","article-title":"Multidisciplinary teams for psoriatic arthritis: on aims and approaches","volume":"105","author":"Ca\u00f1ete","year":"2014","journal-title":"Actas Dermosifiliogr."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.737256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T05:20:08Z","timestamp":1673241608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.737256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":200,"alternative-id":["10.3389\/fmed.2021.737256"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.737256","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"article-number":"737256"}}